Deqi Pharmaceuticals Hong Kong Stock Exchange is listed with a focus on innovation

On November 20, Deqi (Zhejiang) Pharmaceutical Technology Co., Ltd. (Deqi Pharmaceuticals - B,06996.HK) was officially listed on the main board of the Hong Kong Stock Exchange.
is the 26th IPO of a biotech company since the introduction of the 18A New Deal on the Hong Kong Stock Exchange, and the 12th innovative pharmaceutical company to land on the Hong Kong Stock Exchange this year. According to the
prospectine, the listing sold a total of 154 million shares at a price of HK$18.08 per share, with an opening price of HK$19.6 per share, up 8.41% from the offering price, and the share price then fell, with the total market value of Deqi Pharmaceuticals reaching HK$12.21 billion by the time of the offering.
raised about HK$2,636 million for this listing.
The funds raised will be used primarily for clinical trials and commercialization of research products, including promoting the marketization of core products ATG-010 in the Asia Pacific region, promoting nine ongoing clinical trials and six preclinical product development studies, enhancing self-development capabilities and enhancing the potential for collaboration with the world's leading pharmaceutical companies.
addition, the funds will also be used for pipeline expansion, talent recruitment, further strengthen the company's research and development base, improve the speed of clinical research.
12 products in research, the field of oncology focus on the establishment of more than three years, Deqi Pharmaceuticals has 12 clinical and preclinical innovative drugs rich product pipeline, of which 6 products have entered the clinical trial stage.
pipelines are mostly license in projects, focusing on oncology treatment and covering diseases such as viral infections and self-free treatment, with partners including well-known pharmaceutical companies such as Karyopharm and AstraZenecon.
, the core candidates for Deqi Pharmaceuticals, ATG-010 (selinexor) and ATG-008 (onatasertib), are in phase II clinical trials in China.
plans to submit applications for the listing of new ATG-010 drugs in Chinese mainland, Hong Kong, Taiwan, Australia, Singapore, South Korea and Thailand by 2021.
it is understood that the ATG-010 (selinexor) is the first SINE compound of its kind to inhibit the nuclear output protein XPO1, developed by Dechi Pharmaceuticals in partnership with Karyopharm Therapeutics.
The FDA has now approved its single and combined drugs for the treatment of diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM), the first and only SINE compound approved by the U.S. FDA.
, the drug candidate is now in clinical Phase II trials in China for the treatment of MM and DLBCL.
ATG-008 (onatasertib) is a second-generation oral mTOR kinase inhibitor developed by Celgene and the first drug of its type to enter clinical trials for advanced liver cancer in the world, with Deki Pharmaceuticals owning the right to develop the drug in several countries in East and South-East Asia.
At present, ATG-008 is conducting a number of multi-center clinical studies for the treatment of advanced liver cancer (HCC), non-small cell lung cancer (NSCLC), gynaecological tumors and many other tumors in the form of single-drug or combination anti-PD-1 antibodies.
In addition, Deqi Pharmaceuticals has a second generation of oral selective nuclear output protein XPO1 inhibitor ATG-016 (eltanexor), the world's first PAK4/NAMPT dual-target inhibitor ATG-019 and other drugs in clinical trials, early drug research and development team is also continuing to promote small molecules, monoclonal and dual-specific antibodies and other anti-tumor drugs preclinical research and development.
note: There are deletions in the original text